Online Pharmacies To Witness Rapid Growth In The Pbc Therapeutics Market, Valued At $683.95 Million In 2022

By Author: Orson Amiri
Total Articles: 411
Comment this article

The global Primary Biliary Cholangitis (PBC) Therapeutics market, valued at $683.95 million in 2022, is expected to grow to approximately $1.4 billion by 2032, with a 7.1% annual growth rate. PBC Therapeutics are treatments for primary biliary cholangitis, a chronic autoimmune liver disease affecting small bile ducts. Factors driving market growth include a rising number of PBC cases, increased awareness of the disease, and ongoing advancements in therapeutics. Notable developments include Setanaxib in Phase III clinical trials. Key market segments include drug types (primary and secondary drugs) and distribution channels (hospital pharmacies, drug stores, and online pharmacies). North America led in 2022, with Asia-Pacific expected to show the highest growth. Key market players include ABC Farmaceutici S.p.a., GENFIT, and Intercept Pharmaceuticals, Inc.

Read More - https://www.techdogs.com/tech-news/pr-newswire/online-pharmacies-to-witness-rapid-growth-in-the-pbc-therapeutics-market-valued-at-68395-million-in-2022